Treatment Paradigms
Current and evolving treatment approaches across your disease states of interest
Filter by Disease State
Treatment Paradigms
Multiple Myeloma Treatment Paradigm
Current and evolving treatment approaches for multiple myeloma across lines of therapy, with focus on BCMA-targeted therapies, bispecifics, and novel combinations.
Moderate-to-Severe Plaque Psoriasis Treatment Paradigm
Current and evolving treatment approaches for moderate-to-severe plaque psoriasis, with focus on IL-23 inhibitors, TYK2 inhibitors, and emerging oral therapies.
Psoriatic Arthritis Treatment Paradigm
Current and evolving treatment approaches for psoriatic arthritis, with focus on IL-17 inhibitors, IL-23 inhibitors, JAK inhibitors, and novel targeted therapies.
HR+/HER2- Breast Cancer Treatment Paradigm
Current and evolving treatment approaches for HR+/HER2- breast cancer, with focus on CDK inhibitors, PI3K inhibitors, ADCs, and novel endocrine therapy combinations.
Severe Asthma Treatment Paradigm
Current and evolving treatment approaches for severe asthma, with focus on biologics targeting different inflammatory pathways (IL-5, IL-4/13, TSLP) and novel combination approaches.
HER2+ Breast Cancer Treatment Paradigm
Current and evolving treatment approaches for HER2+ breast cancer, with focus on novel HER2-targeted therapies, ADCs, bispecifics, and TKIs across treatment settings.
Regional Treatment Paradigm Comparison
Premium FeatureCompare treatment paradigms across different regions to understand regional variations in standard of care, guideline recommendations, and market access considerations.
United States
Treatment paradigms based on NCCN, ACR, and other US-specific guidelines, with focus on FDA-approved therapies and US payer considerations.
Europe
Treatment paradigms based on ESMO, EULAR, and other European guidelines, with focus on EMA-approved therapies and HTA considerations across key markets.
Asia-Pacific
Treatment paradigms for Japan, China, and other APAC markets, with focus on regional approval status, reimbursement, and local guideline recommendations.
Recent Treatment Paradigm Updates
NCCN Guidelines Update for Multiple Myeloma (Version 3.2025)
The NCCN has updated its guidelines for multiple myeloma to include new recommendations for BCMA-targeted therapies in earlier lines of therapy and updated sequencing recommendations.
AAD-NPF Guidelines Update for Psoriasis
The American Academy of Dermatology and National Psoriasis Foundation have updated their joint guidelines for psoriasis management to include recommendations for newer oral therapies.
ESMO Guidelines Update for Metastatic Breast Cancer
ESMO has updated its clinical practice guidelines for metastatic breast cancer to incorporate recent clinical trial data for novel ADCs and other targeted therapies.
© 2025 CI Agent. All rights reserved.